Oncology research, especially decentralized oncology trials, continue to undergo rapid transformation, driven by a number of factors including:

• Increased interest in understanding the patient experience beyond health-related, quality-of-life measures
• Regulatory guidance updates
• Rapid acceptance of digital solutions such as telehealth and digital health technologies

Learn from Signant’s in-house clinical science and eCOA experts how researchers can take advantage of these new paradigms in clinical research to run more efficient, inclusive, and convenient oncology trials.

This article is taken from International Clinical Trials February 2022, pages 34-36 ©️ Samedan Ltd